Cases primobolan acetateoverdose are not logged in. Single animals inhalation drug in doses exceeding commonly used in humans up to 180 times, well tolerated. Dornase alpha oral administration to rats at doses up to 200 mg / kg was well tolerated well. In clinical studies of patients with cystic fibrosis to give 20 mg dornase alpha, 2 times a day for 6 days and 10 mg 2 times a day on an intermittent schedule (two weeks reception interval of two weeks) over 168 days. Both dosage regimens were well tolerated.
Interaction with other drugs
Compatible with standard drugs for the treatment of cystic fibrosis:. Antibiotics, bronchodilators, digestive enzymes, vitamins, inhaled and systemic corticosteroids and analgesics
Pulmozyme is an aqueous solution without the buffer properties and should not be bred or mixed with other drugs or solutions in the nebulizer container. Mixing of the drug with other drugs can lead to undesirable structural and / or functional changes Pulmozim or other component of the mixture.
In therapy need to continue regular medical observation of the patient.
After initiation of therapy, as with any aerosol, pulmonary function may be somewhat reduced, and expectoration of sputum increased.
Experience with Pulmozim in children under the age of 5 years is limited.
There were no differences in the safety profile at children under 5 years and older age group 5 to 9 years. After the end of treatment revealed no increase in the frequency of serious adverse events in children under 5 years who received Pulmozyme.
Appoint primobolan acetate children under 5 years old should only be the case if the potential benefit of improving pulmonary function exceeds the risk of respiratory tract infection.
The efficacy and safety of dornase alfa in patients with less than 40% of the norms have not been established.
a single short action of elevated temperatures (up to 24 hours at temperatures up to 30єS) does not affect the stability of the drug.
Effects on ability to drive and use machines
The effect of dornase alfa on the patient’s ability to drive and operate with mechanisms messages have been received.
Release form and packing solution for inhalation 2.5 mg / 2.5 mL In 2.5 ml of the drug in a colorless plastic vial, manufactured by termoshtampovki. 6 vials are placed in a protective container made of a multilayer aluminum foil. 1 protective primobolan acetate container together with instructions for use placed in a cardboard box.